Head-to-head · WeighScore
bmiMD vs Mint Med
The verdict
Too close to call — both grade 84/100 (B).
bmiMD and Mint Med land on the same WeighScore, so neither clears the other on our six graded dimensions. Mint Med sits one line higher on the board (#15 vs #16) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.
Both are editorial reviews with no commercial relationship.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | bmiMD | Mint Med |
|---|---|---|
| WeighScore | 84/100 | 84/100 |
| Grade | B | B |
| Scorecard rank | #16 | #15 |
| Semaglutide | $99/mo | $117/mo |
| Tirzepatide | $139/mo | $159/mo |
| Coverage | All 50 states | 36 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| Relationship | Editorial | Editorial |
Graded #16 · B
Strengths
- $99 sema / $139 tirz
- All 50 states
- Both molecules
Where it loses points
- Not LegitScript-verified
- Injection-only
- Thin oversight/monitoring detail
Graded #15 · B
Strengths
- $117 sema / $159 tirz
- LegitScript-verified
- Both molecules
Where it loses points
- Only 36 states
- Injection-only
- Monitoring detail sparse
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.